Politics & Law
More Than a Pop Star Problem: Miley Cyrus, Ovarian Cysts, and the Silence Around Gynecological Pain
It wasn’t a red carpet moment, but it made headlines just the same. In a candid interview, pop icon Miley...
Read more
Pharmaceutical Power and the Fight for Reform: Untangling the Complex Web of U.S. Drug Pricing
Few corners of the U.S. healthcare system are as opaque—or as fiercely contested—as the terrain of drug pricing. This spring,...
Read more
The WHO Pandemic Treaty Debate: Global Unity or Sovereign Resistance?
As memories of COVID-19's global chaos linger, the international community is grappling with an ambitious yet polarizing idea: a legally...
Read more
Prescriptions and Power: Why Eli Lilly Is Suing Compounding Pharmacies Over Weight Loss Drugs
In the escalating battle over obesity treatment in the United States, the pharmaceutical industry has found an unexpected foe: local...
Read more
Science vs. Slogan: The Growing Rift Between RFK Jr. and the Public Health Establishment
On April 15, a coalition of 17 national public health organizations, spearheaded by the American Public Health Advocacy Network (APHAN),...
Read more
The Silence Clause: NIH Halts Grants to Top Universities Amid Veiled Directives
On a quiet Tuesday afternoon in March, a cryptic internal email circulated through the National Institutes of Health (NIH), addressed...
Read more
Medical Journals Under Scrutiny: DOJ’s Quiet Inquiry Into Scientific Dissent
In the wake of COVID-19 and the increasing politicization of public health, the U.S. Department of Justice has taken an...
Read more
The Physician on Trial: A Broken System, A Profession Reborn
Bad news travels fast. But good news? That takes time. And when it comes to the federal prosecution of physicians,...
Read more
What Happens When the Match Ends? States Brace for Impact as CMS Shifts Medicaid Funding Rules
When a federal agency changes the way money flows, the effects aren’t always immediate — but they’re often profound. In...
Read more
Where Medicine Meets Morality: How Specialty Societies Responded to the Gaza-Israel Conflict
In the early days of the Gaza-Israel conflict, images of devastation filled screens and newspapers around the world. Hospitals overwhelmed,...
Read more
The Data Dilemma: What 23andMe’s Bankruptcy Means for the Future of Medical Data Ownership
The news of 23andMe’s financial instability and potential bankruptcy isn’t just another tech-company flameout. It’s a watershed moment for the...
Read more
From Academia to Algorithms: Vinay Prasad and the Rise of Populist Medicine Online
Healthcare has always existed at the intersection of science, politics, and public trust. But in today’s digital era, the loudest...
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read morePopular
-
National Opioid Settlement Injunction
-
Strategies for Transitioning Off GLP-1 Injections
-
Biosimilar Economics Through a Benchmark Lens: What WAC and NADAC Reveal About Competition
-
The IRA’s Negotiation Mechanism and What Benchmark Data Will Reveal About Its Actual Effect
-
PBMs as Price Signal Absorbers: How Formulary Architecture Distorts Benchmark Data
